![](/images/graphics-bg.png)
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
المؤلفون المشاركون
Lambropoulos, Alexandros
Karayannopoulou, Georgia
Murray, Samuel
Misailidou, Despina
Aravantinos, Gerasimos
Athanassiou, Eleni
Kalogera-Fountzila, Anna
Fountzilas, George
Markou, Konstantinos
Wirtz, Ralph M.
Skarlos, Demosthenis
Lambaki, Sophia
Nikolaou, Angelos
Bobos, Mattheos
Kalogeras, Konstantine T.
Kotoula, Vassiliki
المصدر
العدد
المجلد 2009، العدد 2009 (31 ديسمبر/كانون الأول 2009)، ص ص. 1-17، 17ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2009-12-29
دولة النشر
مصر
عدد الصفحات
17
التخصصات الرئيسية
الملخص EN
Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice for patients with locally advanced head and neck cancer.
In the present retrospective analysis, we investigated the predictive role of several biomarkers in an unselected cohort of patients treated with concomitant radiotherapy, weekly cisplatin, and cetuximab (CCRT).
We identified 37 patients treated with this approach, of which 13 (35%) achieved a complete response and 10 (27%) achieved a partial response.
Severe side effects were mainly leucopenia, dysphagia, rash, and anemia.
Tumor EGFR, MET, ERCC1, and p-53 protein and/or gene expression were not associated with treatment response.
In contrast, high MMP9 mRNA expression was found to be significantly associated with objective response.
In conclusion, CCRT is feasible and active.
MMP9 was the only biomarker tested that appears to be of predictive value in cetuximab treated patients.
However, this is a hypothesis generating study and the results should not be viewed as definitive evidence until they are validated in a larger cohort.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Fountzilas, George& Kalogera-Fountzila, Anna& Lambaki, Sophia& Wirtz, Ralph M.& Nikolaou, Angelos& Karayannopoulou, Georgia…[et al.]. 2009. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of Oncology،Vol. 2009, no. 2009, pp.1-17.
https://search.emarefa.net/detail/BIM-462001
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Fountzilas, George…[et al.]. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of Oncology No. 2009 (2009), pp.1-17.
https://search.emarefa.net/detail/BIM-462001
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Fountzilas, George& Kalogera-Fountzila, Anna& Lambaki, Sophia& Wirtz, Ralph M.& Nikolaou, Angelos& Karayannopoulou, Georgia…[et al.]. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Journal of Oncology. 2009. Vol. 2009, no. 2009, pp.1-17.
https://search.emarefa.net/detail/BIM-462001
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-462001
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)